The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan.
As of April 2, 25 subjects have successfully completed the one-year treatment protocol.
The study is scheduled for unblinding in the first quarter of 2027.